GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Institutional Ownership

Serina Therapeutics (Serina Therapeutics) Institutional Ownership : 1.23% (As of Jun. 05, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Serina Therapeutics's institutional ownership is 1.23%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Serina Therapeutics's Insider Ownership is 0.58%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Serina Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


Serina Therapeutics Institutional Ownership Historical Data

The historical data trend for Serina Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Institutional Ownership Chart

Serina Therapeutics Historical Data

The historical data trend for Serina Therapeutics can be seen below:

2024-03-31 2024-04-30
Institutional Ownership 1.23 1.23

Serina Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Serina Therapeutics (Serina Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines